ストックスクリーナーアプリを入手
0.5073
9.57%
-0.0537
アフターアワーズ：
.51
0.0027
+0.53%
前日終値:
$0.561
開ける：
$0.545
24時間の取引高:
250.77K
Relative Volume:
1.92
時価総額：
$9.81M
収益：
$420.00K
当期純損益:
$-19.65M
株価収益率:
-0.00367
EPS:
-138.243
ネットキャッシュフロー:
$-26.08M
1週間 パフォーマンス:
-26.49%
1か月 パフォーマンス:
-31.72%
6か月 パフォーマンス:
-97.06%
1年 パフォーマンス:
-99.93%
1日の値動き範囲:
$0.5006
$0.5569
1週間の範囲:
$0.5006
$0.76
52週間の値動き範囲:
$0.5006
$1,030.00
Kala Bio Inc Stock (KALA) Company Profile
Compare KALA vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.5073 | 16.25M | 420.00K | -19.65M | -26.08M | -138.24 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-30 | ダウングレード | Mizuho | Outperform → Neutral |
| 2025-09-29 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-09-29 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2025-09-08 | 開始されました | Mizuho | Outperform |
| 2025-07-11 | 開始されました | Ladenburg Thalmann | Buy |
| 2022-03-30 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-08-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-09-14 | ダウングレード | Jefferies | Buy → Hold |
| 2020-07-23 | 開始されました | Northland Capital | Outperform |
| 2020-06-01 | 再開されました | Oppenheimer | Outperform |
| 2020-05-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-09 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | 開始されました | Jefferies | Buy |
すべてを表示
Kala Bio Inc (KALA) 最新ニュース
KALA (KALA) Technicals: Moves 6.67% Down to $0.84; Technical Setup: the Supplied Trading Band Runs From $0.80 to $0.88 at the CloseProtective Put - vinanet.vn
KALA Stock Hits Record Low – Firm Announces Reverse Split After Shares Fail To Surpass The $1 Mark - Stocktwits
KALA BIO: Q2 Earnings Snapshot - AOL.com
KALA BIO Q2 Net Loss Narrows to $1.58 Million Amid Sharp Spending Cuts - Minichart
KALA BIO, Inc. Q2 2026: Net loss $(1.58M), EPS $(21.32) — 10-Q Summary - TradingView
KALA: Net loss narrowed sharply as focus shifted to AI platform, with liquidity supported by note receivable - TradingView
KALA BIO (KALA) pivots to biotech AI with $229K on hand - Stock Titan
KALA (KALA) Session: Retreats 0.97% to $0.89; Next Session: Price Remains Between $0.85 Support and $0.93 Resistance in the Latest ReadingRTH Profile - vinanet.vn
KALA Q4 2025 Earnings: Loss Narrows to -33.5 Per Share, Beating Estimates by 54.38Performance Review - vinanet.vn
KALA BIO Announces Brief Delay in Quarterly Filing - TipRanks
KALA BIO (KALA) delays June 30, 2026 Form 10-Q to finalize liquidity analysis - Stock Titan
KALA Q4 2025 Earnings: Narrower-Than-Expected Loss Delivers a 54.38 EPS SurpriseDividend Growth Analysis - vinanet.vn
KALA BIO Inc (KALA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
KALA BIO (KALA) Climbs 4.4% to $0.73 as Bulls Target $0.77 ResistanceRevenue Weighted - Vinanet
KALA Q2'26 Earnings: EPS estimate is (6.00) USD - TradingView
KALA BIO Inc. (KALA) Gains 3.59% to $0.76 — Approaches Key Resistance at $0.80Systematic Flow - vinanet.vn
KALA BIO Inc (KALA) Institutional Confidence - TradingKey
KALA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
KALA BIO Inc (KALA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
KALA BIO Inc (KALA) Cash Flow - TradingKey
KALA BIO Inc (KALA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
KALA BIO Inc (KALA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
KALA Q4 2025 Earnings: Significant Beat on EPS Despite No Reported RevenueRevenue Inflection Point - vinanet.vn
TradingKey - TradingKey
KALA BIO Inc (KALA) Balance Sheet - TradingKey
KALA|KALA BIO Inc|Price:0.740|Chg%:-0.003 - TradingKey
KALA|KALA BIO Inc|Price:0.671|Chg%:+0.036 - TradingKey
KALA BIO, Inc. Revenue Breakdown – NASDAQ:KALA - TradingView
KALA|KALA BIO Inc|Price:0.634|Chg%:+0.024 - TradingKey
KALA BIO Inc (KALA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kala Bio, Inc. Files Form 8-K with SEC Detailing Nasdaq Listing and Corporate Information - Minichart
KALA Q4 2025 Earnings: EPS Beat Masks Revenue Woes as Stock Slides 17%Financial Data - vinanet.vn
Kala Bio Files ATM Offering Of Up To $250 Million In Common StockSEC Filing - TradingView
Frontier tech research, news & data - MLQ.ai
KALA BIO Shares Plunge Over 7% as Stock Nears Critical Support LevelGamma Flip Level - vinanet.vn
Kala Bio announces 1-for-50 reverse stock split effective Friday - Investing.com
Form 13D/A KALA BIO For: 2 July By Investing.com - Investing.com Nigeria
David Lazar trims KALA BIO (KALA) stake to 3.9% with 719,404 shares - Stock Titan
Price to earnings forward of KALA BIO, Inc. – NASDAQ:KALA - TradingView
KALA BIO Inc. (KALA) Holds Near Support After Slight Decline: Key Levels in FocusVanna Flow - dars.gov.et
[EFFECT] KALA BIO, Inc. SEC Filing - Stock Titan
Enterprise value to EBIT forward of KALA BIO, Inc. – NASDAQ:KALA - TradingView
Enterprise value to EBITDA forward of KALA BIO, Inc. – NASDAQ:KALA - TradingView
Price to book forward of KALA BIO, Inc. – NASDAQ:KALA - TradingView
Enterprise value to revenue forward of KALA BIO, Inc. – NASDAQ:KALA - TradingView
KALA Q4 2025 Earnings: EPS Beats Estimates, Stock Surges 26.9%Slow Growth Warning - dars.gov.et
KALA BIO StockLong-term eye-disease strategy in focus - AD HOC NEWS
KALA BIO Inc (KALA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kala Bio Inc (KALA) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):